U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. speaks as he attends a press conference with Centers for Medicare and Medicaid Services Administrator Mehmet Oz to discuss health insurance reform, at the Department of Health and Human Services in Washington, D.C., U.S., June 23, 2025.

美国卫生与公众服务部（HHS）部长小罗伯特·F·肯尼迪在2025年6月23日于华盛顿特区的美国卫生与公众服务部，与医疗保险和医疗补助服务中心管理员梅赫梅特·奥兹共同出席新闻发布会，讨论健康保险改革时发表讲话。

.

。

Kevin Mohatt | Reuters

凯文·莫哈特 | 路透社

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox.

本文的一个版本首次出现在CNBC的《健康回报》新闻简报中，该简报会将最新的医疗保健新闻直接发送到您的邮箱。

Subscribe here

在这里订阅

to receive future editions.

接收未来版本。

Health and Human Services Secretary Robert F. Kennedy Jr. recently

卫生与公共服务部长小罗伯特·F·肯尼迪最近

gutted a key government vaccine panel

裁撤了一个关键的政府疫苗小组

, saying it was necessary to eliminate what he called 'persistent conflicts of interest' on the committee.

，称有必要消除他所说的委员会中存在的“持续的利益冲突”。

But

但是

new research

新研究

from the USC Schaeffer Center for Health Policy & Economics appears to challenge that argument. Conflicts on that Centers for Disease Control and Prevention panel had been at 'historic lows for years' before Kennedy restacked it with new members, some of whom are widely known vaccine critics, the researchers found..

来自南加州大学施赖弗健康政策与经济中心的研究似乎对该论点提出了挑战。研究人员发现，在肯尼迪重新安排该疾控中心预防控制中心小组的新成员之前，该小组的冲突已经处于“多年来的历史低点”，其中一些新成员是广为人知的疫苗批评者。

The study, published in the medical journal JAMA on Monday, also found that the type of conflict considered to be the 'most concerning' – income from vaccine makers – had been virtually eliminated among members of the Advisory Committee on Immunization Practices, or ACIP.

周一发表在医学杂志《美国医学会杂志》上的这项研究还发现，被认为“最令人担忧”的冲突类型——来自疫苗制造商的收入——在免疫实践咨询委员会 (ACIP) 的成员中几乎已被消除。

Conflicts of interest rates were also low on a separate panel of advisors to the Food and Drug Administration called the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, according to the research.

根据研究，食品和药物管理局另一个顾问小组——疫苗及相关生物制品咨询委员会（VRBPAC）的利益冲突率也较低。

Both groups are crucial to shaping U.S. vaccine policy: While the FDA committee advises the agency on whether to approve shots, the CDC panel determines who is eligible for jabs and whether insurers should cover them. The panels are typically made up of top experts in infectious diseases, pediatrics, immunology and public health..

这两个小组对制定美国疫苗政策都至关重要：FDA委员会就是否批准疫苗向该机构提供建议，而CDC小组则决定谁有资格接种疫苗以及保险公司是否应该覆盖疫苗费用。这些小组通常由传染病、儿科、免疫学和公共卫生领域的顶级专家组成。

Kennedy has long contended that the advisors on those panels have close ties to the pharmaceutical industry. At his first Senate confirmation hearing in January, Kennedy claimed that 97% of the CDC panel members had conflicts of interest.

肯尼迪长期以来一直认为，这些小组中的顾问与制药行业有着密切的联系。在今年一月的首次参议院确认听证会上，肯尼迪声称疾控中心小组成员中有97%存在利益冲突。

'Before he was confirmed, I saw this 97% number and thought, wow, that's some serious stuff. But after looking at the vaccine data myself, I certainly couldn't see anything at that scale,' said the study's lead author Genevieve Kanter, an associate professor of public policy at the University of Southern California, in an interview..

“在他被确认之前，我看到了这个97%的数字，心想，哇，这是很严重的事情。但在亲自查看了疫苗数据后，我确实看不出有任何如此规模的问题，”该研究的主要作者、南加州大学公共政策副教授吉纳维芙·坎特在接受采访时说。

'I think it will be reassuring to the public and to the [Trump] administration that issues that we thought were pretty serious or in the past were serious are not anymore,' she added.

“我认为，这将让公众和[特朗普]政府放心，我们认为过去那些非常严重的问题已经不再严重了，”她补充道。

The research comes as Kennedy, a prominent vaccine skeptic himself, overhauls federal health agencies and pursues efforts that could change immunization policy and undermine vaccine uptake in the U.S.

这项研究出台之际，肯尼迪这位著名的疫苗怀疑论者正在对联邦卫生机构进行大刀阔斧的改革，并采取可能改变美国免疫政策和削弱疫苗接种率的行动。

The USC researchers analyzed reported financial conflicts of interest among experts on the two vaccine panels between 2000 and 2024.

南加州大学研究人员分析了2000年至2024年间两个疫苗专家组成员报告的财务利益冲突情况。

Here's how conflicts of interest disclosures work on the panels, which meet several times a year to review vaccines: For each product being discussed, members must say if they have a tie to the vaccine maker or a competitor and disclose the nature of the relationship. People on the panel with conflicts either receive a waiver to participate if they are deemed to provide essential expertise, while those with conflicts considered too significant are recused. .

以下是利益冲突披露在这些小组中的运作方式，这些小组每年开会数次以审查疫苗：对于每个正在讨论的产品，成员必须说明他们是否与疫苗制造商或其竞争对手有联系，并披露关系的性质。如果被认为提供关键专业知识，有利益冲突的小组成员可以得到豁免参与，而那些利益冲突被认为过于重大的则会被回避。

Since 2016, an average of 6.2% of ACIP members and 1.9% of VRBPAC members have reported a financial conflict of interest at any given meeting, according to the paper. During that period, less than 1% of reported conflicts on both panels were tied to personal income from vaccine makers, including consulting fees, stock, royalties or ownership. .

根据该论文，自 2016 年以来，在任何特定会议上，平均有 6.2% 的 ACIP 成员和 1.9% 的 VRBPAC 成员报告了财务利益冲突。在此期间，两个小组中不到 1% 的报告冲突与来自疫苗制造商的个人收入有关，包括咨询费、股票、版税或所有权。

Rates of reported conflicts among ACIP members fell to 5% by 2024, and stayed below 4% among VRBPAC members since 2010, including 10 years where there were no reported conflicts at all.

到 2024 年，ACIP 成员报告的冲突比例下降至 5%，而自 2010 年以来，VRBPAC 成员的冲突比例一直低于 4%，其中包括连续 10 年完全没有报告任何冲突。

Conflict of interest rates were significantly higher in the early 2000s, peaking at around 43% for ACIP in 2000 and 27% for VRBPAC in 2007, the researchers found.

研究人员发现，2000年代初期的利益冲突率显著更高，ACIP在2000年达到约43%的峰值，而VRBPAC在2007年达到约27%的峰值。

The study said the decline over the years may be due to policy changes in 2007 that cracked down on conflicts of interest on the FDA panel, and 'greater awareness and scrutiny' of conflicts in agency decision-making. It's not clear when exactly the CDC committee began to do the same.

研究表示，多年来这一比例的下降可能是由于 2007 年政策的改变，严厉打击了 FDA 专家小组的利益冲突，同时“更加意识到并仔细审查”机构决策中的利益冲突。目前尚不清楚 CDC 委员会具体在何时开始采取相同措施。

Across the study period, the most frequently reported conflict of interest was research support, which is generally considered less of a concern than financial ties associated with personal income. Kanter said that's a reflection of the panel members' areas of expertise that are relevant to evaluating the safety, efficacy and applicability of shots. .

在整个研究期间，最常报告的利益冲突是研究支持，这通常被认为比与个人收入相关的财务联系问题要小。康特说，这反映了专家组成员在评估疫苗的安全性、有效性和适用性方面的专业领域。

'The dominant conflicts were grant support for research. In a way that makes sense because, who do we want on these committees? It's people with expertise on how to conduct research on these vaccines,' Kanter said.

“主要的冲突在于提供研究资助支持。在某种程度上这是合理的，因为我们希望谁在这些委员会中呢？是那些知道如何对这些疫苗进行研究的专家，”坎特说。

'These conflicts are not about personal gain, but related to measures of expertise.'

“这些冲突并非关乎个人利益，而是与专业度的衡量措施有关。”

While some of the rates appear to be higher with ACIP members than with people on the VRBPAC panel, Kanter said it is not comparable because the CDC provides 'far less granular' data on conflicts of interest. She added that the FDA panel typically reviews one product at a time during a meeting, while the CDC committee evaluates multiple. .

虽然 ACIP 成员的某些比率似乎比 VRBPAC 小组的人员要高，但坎特表示这不可比较，因为 CDC 提供的利益冲突数据“远不够细致”。她补充说，FDA 小组通常会在会议期间一次审查一个产品，而 CDC 委员会则评估多个产品。

Kanter said it is important to examine conflicts of interest and the influence of the pharmaceutical industry in many aspects of health-care regulation.

康特说，重要的是要检查利益冲突和制药行业在医疗保健监管的许多方面的影响。

But she added that 'if we do want to focus on conflicts of interest, there may be other areas where the prevalence is a greater concern than what we've seen here with these vaccine panels.'

但她补充说，“如果我们确实想关注利益冲突，其他领域的普遍性或许比我们在此看到的这些疫苗小组中的情况更令人担忧。”

Feel free to send any tips, suggestions, story ideas and data to Annika at

请随时将任何提示、建议、故事构思和数据发送给Annika，

annikakim.constantino@nbcuni.com

annikakim.constantino@nbcuni.com

.

。

Latest in health care: UnitedHealth's Buffett bounce holds for now

医疗保健领域的最新动态：联合健康集团的巴菲特效应目前仍在持续

Warren Buffett was just what the doctor ordered to stabilize

沃伦·巴菲特正是稳定局势所需要的良方

UnitedHealth Group

联合健康集团

shares.

股票。

Berkshire Hathaway's 13F filing revealing a new stake of more than 5 million shares has helped lift the stock back above $300 — a far cry from the 52-week low of under $235 that it hit earlier this month.

伯克希尔哈撒韦公司提交的13F文件显示，其新持有超过500万股的股份，这一消息帮助该股票回升至300美元以上——较本月初触及的52周低点不到235美元已有显著反弹。

This marks Berkshire's first foray into the complicated area of managed care. David Tepper's Appaloosa Fund also provided a vote of confidence in the embattled health care giant's stock, boosting its stake to 2.5 million shares.

这标志着伯克希尔首次涉足管理式医疗这一复杂领域。大卫·泰珀的阿帕卢萨基金也对这家备受争议的医疗巨头股票投下了信任票，将其持股增加至250万股。

For both, it's a bet on recovery, but analysts say the wait could take well over a year.When assessing the purchases, Baird analyst Michael Ha invoked Warren Buffett's own words about 'complicated, uncertain investments' which belong in the 'too hard pile.'

对于这两者来说，这是对经济复苏的押注，但分析师表示，等待的时间可能超过一年。在评估这些收购时，贝尔德分析师迈克尔·哈引用了沃伦·巴菲特关于“复杂、不确定的投资”的话，这些投资属于“太难处理”的一类。

In a note to clients, Ha wrote that UnitedHealth's issues extend beyond pricing in its Medicare Advantage plans to real structural problems with its Optum health physician unit that aren't as easily fixed. Ha added that 'near-term execution risk is high and we see potential for the situation to worsen over the next 12-18 months before improving.'.

在给客户的一份报告中，哈写道，联合健康集团的问题不仅限于其 Medicare Advantage 计划的定价，还涉及到其 Optum 健康医生部门真正的结构性问题，而这些问题并不容易解决。哈还补充说：“短期内的执行风险很高，我们认为在未来 12 到 18 个月内，情况可能会进一步恶化，然后才会有所改善。”

For now, on a technical basis, UnitedHealth shares are trading above their 50-day moving average for the first time since the company first lowered guidance in April.

目前，从技术角度而言，自联合健康集团4月首次下调指导预期以来，其股价首次高于50日均线。

Feel free to send any tips, suggestions, story ideas and data to Bertha at

随时欢迎将任何提示、建议、故事构思和数据发送给Bertha

bertha.coombs@nbcuni.com

贝莎·库姆斯@nbcuni.com

.

。

Latest in health-care tech: Epic touts new AI tools at annual Users Group Meeting

最新医疗技术：Epic在年度用户组会议上展示新的人工智能工具

Epic's campus in Verona, Wisconsin

威斯康星州维罗纳的Epic园区

Courtesy: Epic

礼貌：史诗级

This is Ashley, reporting live from Verona, Wisconsin.

这是艾希礼，从威斯康星州维罗纳现场报道。

It's that time of year again! I'm attending Epic's annual

又到了一年中的这个时候！我将参加Epic的年度

Users Group Meeting

用户组会议

, where thousands of health-care executives flock to the company's 1,670-acre headquarters to learn about the company's latest products and features.

，成千上万名医疗保健主管涌入该公司占地1670英亩的总部，了解该公司的最新产品和功能。

Epic is a health-care software company best known for its electronic health record, or EHR software. An EHR is a digital version of a patient's medical record that's maintained by doctors and nurses over time. Epic is the dominant EHR vendor in the U.S., and its technology is used in 3,300 hospitals and 73,000 clinics and by 325 million patients around the globe, according to the company..

Epic是一家医疗保健软件公司，最著名的是其电子健康记录（EHR）软件。EHR是患者医疗记录的数字版本，由医生和护士长期维护。Epic是美国主要的EHR供应商，据该公司称，其技术被应用于3,300家医院、73,000家诊所，并为全球3.25亿患者提供服务。

Artificial intelligence was front and center at UGM this year, much like it was

今年的UGM上，人工智能再次成为焦点，就像以往一样。

last year

去年

. During a three-hour-long executive address Tuesday morning, Epic executives shared updates about the roughly 200 new AI features it's been developing for patients, clinicians and payers. Keep an eye out for additional coverage from CNBC that explains some of these upcoming features in more detail. .

在周二上午长达三个小时的高管演讲中，Epic的高管们分享了关于其正在为患者、临床医生和支付方开发的大约200项新AI功能的更新。请继续关注CNBC的更多报道，其中将更详细地解释这些即将推出的功能。

Epic confirmed that it is developing its own AI-powered clinical documentation tool, which was one of the most anticipated announcements of this year's event. These tools, which are often called AI scribes, are able to draft clinical notes in real time as doctors consensually record their visits with patients. .

Epic证实，该公司正在开发自己的人工智能临床文档工具，这是今年活动中最受期待的公告之一。这些工具通常被称为人工智能记录员，能够在医生与患者就诊时实时记录并起草临床笔记。

A fiercely competitive AI scribing market has taken off as health-care executives search for solutions to help reduce staff burnout and daunting administrative workloads. Some AI scribing startups like Abridge and Ambience Healthcare have raised hundreds of millions of dollars from investors, and there was a lot of speculation about whether Epic would ultimately join the fray. .

随着医疗保健行业的高管们寻找解决方案，以帮助减轻员工的倦怠感和繁重的行政工作量，一个竞争异常激烈的AI听写市场已经迅速兴起。一些AI听写初创公司如Abridge和Ambience Healthcare已经从投资者那里筹集了数亿美元，关于Epic是否会最终加入竞争也引发了诸多猜测。

The company said it is working on this feature in partnership with Microsoft, and that it will be available for limited use early next year.

该公司表示，他们正在与微软合作开发这项功能，并且该功能将在明年年初提供有限的使用。

'AI is here, it's accelerating, you can't wish it away, you've got to keep up with it,' Epic's President Sumit Rana said during the address.

“人工智能已经到来，它正在加速发展，你无法回避它，必须跟上它的步伐，”Epic总裁Sumit Rana在演讲中表示。

The presentations took place in Epic's 11,400-seat underground auditorium called Deep Space, which is just one of the many

这些展示活动在 Epic 的名为“深空”的 11,400 个座位的地下礼堂举行，这只是众多场所中的一个。

unique facilities

独特的设施

on campus. Epic's office buildings are themed, with many inspired by science fiction and stories like 'The Wizard of Oz,' the Harry Potter series and 'Alice in Wonderland.'

校园内。Epic的办公楼以主题为特色，其中许多灵感来源于科幻和故事，如《绿野仙踪》、《哈利波特》系列和《爱丽丝梦游仙境》。

UGM meetings are also themed, and Epic executives famously take the stage dressed in costume. This year's theme was 'sci-fi,' and Epic's 82-year-old founder and CEO Judy Faulkner wore a purple wig, bright green shoes and a metallic vest that appeared inspired by the fictional character, Buzz Lightyear. .

UGM会议也有主题，Epic的高管们以穿着奇装异服登台而闻名。今年的主题是“科幻”，Epic公司82岁的创始人兼首席执行官朱迪·福克纳戴着紫色假发，穿着亮绿色鞋子和似乎受虚构角色巴斯光年启发的金属马甲。

CNBC had the opportunity to sit down with Faulkner earlier this summer in a

CNBC在今年夏天早些时候有机会与福克纳坐下来交谈

rare interview,

罕见的采访，

where she reflected on her 46 years at the company's helm. During her presentation on Tuesday, Faulkner discussed Epic's AI initiatives and roadmap.

她在公司掌舵46年的时间里进行了反思。在周二的演讲中，福克纳讨论了Epic的AI计划和路线图。

'We are combining the intelligence and curiosity of the human being with the investigative capabilities of gen AI,' she said.

“我们正在将人类的智慧和好奇心与生成式人工智能的调查能力结合起来，”她说道。

Many of the new features Epic teased on Tuesday are still several months, or over a year, away. But it's clear that Epic is leaning in on AI, and they didn't let this year's UGM attendees forget it.

Epic 在周二预告的许多新功能仍需数月，甚至一年多的时间才能实现。但很明显，Epic 正在大力投入 AI，并且他们没有让今年的 UGM 参会者忘记这一点。

Read more about CNBC's interview with Faulkner

阅读CNBC对福克纳的采访更多信息

here

这里

.

。

Feel free to send any tips, suggestions, story ideas and data to Ashley at

随时欢迎将任何提示、建议、故事构思和数据发送给Ashley

ashley.capoot@nbcuni.com

阿什利·卡普特@nbcuni.com

.

。